Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Padmanabh P. Bhatt sold 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $623,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) traded down 0.82% during midday trading on Monday, reaching $48.20. The company’s stock had a trading volume of 494,557 shares. The stock’s 50 day moving average price is $43.55 and its 200 day moving average price is $36.98. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $49.95. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of 24.32 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) SVP Sells $249,300.00 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/11/supernus-pharmaceuticals-inc-supn-svp-sells-249300-00-in-stock.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after purchasing an additional 31,331 shares in the last quarter. Vanguard Group Inc. lifted its stake in Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Supernus Pharmaceuticals by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after purchasing an additional 78,084 shares in the last quarter. Ranger Investment Management L.P. lifted its stake in Supernus Pharmaceuticals by 2.8% in the 1st quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after purchasing an additional 40,131 shares in the last quarter. Finally, State Street Corp lifted its stake in Supernus Pharmaceuticals by 3.1% in the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after purchasing an additional 42,165 shares in the last quarter. 95.38% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on SUPN shares. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research report on Wednesday, July 5th. BidaskClub downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Cowen and Company restated a “positive” rating and set a $50.00 price objective (up from $40.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 3rd. Jefferies Group LLC upped their price objective on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Finally, Piper Jaffray Companies restated a “hold” rating and set a $45.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $48.29.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.